Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Therapeutic Drug Monitoring Market worth 2.55 Billion USD by 2020

Wednesday, March 15, 2017 13:33
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Browse 80 tables and 55 figures spread through 142 Pages and in-depth TOC on Therapeutic Drug Monitoring Market by Product (Consumables, Equipment), Technology (Immunoassays, Proteomic Technologies), Class of Drug (Antiepileptics, Antibiotics, Immunosuppressants), End User (Hospital Labs, Private Labs) – Global Forecast to 2020″
http://www.marketsandmarkets.com/Market-Reports/therapeutic-drug-monitoring-market-155350443.html
Early buyers will receive 10% customization on reports.

This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the therapeutic drug monitoring market along with the estimates and forecasts of the revenue.

The technological advances in tests used to monitor therapeutic drugs, increased knowledge of pharmacogenetics and pharmacokinetics of drugs, need for better healthcare in developing countries, and rising prevalence of psychiatric diseases and cancer are the major drivers for the therapeutic drug monitoring market. Adjunct technologies such as biomarker identification using proteomics to accurately identify clinical outcomes and genetic testing are expected to benefit the growth of the therapeutic drug monitoring market. However, high infrastructure costs and dearth of skilled resources may restrain the market growth.

In this report, the therapeutic drug monitoring market is broadly segmented by product, technology, class of drug, end user, and region. On the basis of product, the therapeutic drug monitoring market is divided into consumables and equipment. The equipment segment is further segmented into immunoassay analyzers, proteomic equipment, and other equipment.

On the basis of technology, the therapeutic drug monitoring market is categorized into three segments namely, immunoassays, proteomic technologies, and others. The immunoassays segment is classified into chemiluminescent assay (CLIA), cloned enzyme donor immunoassay (CEDIA), fluorescence polarization immunoassay (FPIA), particle-enhanced turbidimetric inhibition immunoassay (PETINIA), and others. The proteomic technologies segment is further split into liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry.

On the basis of class of drug, the therapeutic drug monitoring market is segmented into antiepileptics, antibiotics, immunosuppressants, antiarrhythmic drugs, bronchodilators, psychoactive drugs, and others. By end user, the therapeutic drug monitoring market is segmented into hospital labs, commercial/private labs, and other end users.

North America is expected to account for more than half the therapeutic drug monitoring market share in 2015. It is the prime market for therapeutic drug monitoring due to the high awareness and acceptance of the benefits of therapeutic drug monitoring and growing healthcare expenditure. The market in Europe on the other hand is growing at a slower rate as the healthcare sector is recovering from the economic downturn and healthcare facilities are trying to minimize healthcare delivery costs. Growth in the APAC therapeutic drug monitoring market is comparatively slower due to dearth of skilled healthcare personnel performing therapeutic drug monitoring tests with minimal errors.

Major players in the therapeutic drug monitoring market include F. Hoffmann-La Roche AG (Switzerland), Siemens Healthcare (Germany), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories Inc. (U.S.), and Danaher Corporation (U.S.).

About MarketsandMarkets

MarketsandMarkets is the world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
Markets and Markets 
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.